Article
Origin of Residual Tumor Masses in BRCA1/2-Driven Ovarian Carcinomas Treated by Neoadjuvant Chemotherapy: Selection of Preexisting BRCA1/2-Proficient Tumor Cells but Not the Gain of Second ORF-Restoring Mutation.
Pathobiology : journal of immunopathology, molecular and cellular biology - 1 Jan 2024
Sokolenko Anna, Preobrazhenskaya Elena, Marchetti Claudia, Piermattei Alessia, Zagrebin Fedor, Kuligina Ekatherina, Gorodnova Tatiana, Pavone Matteo, Ivantsov Alexandr, Bizin Ilya, Scambia Giovanni, Berlev Igor, Fagotti Anna, Imyanitov Evgeny
Abstract excerpt
INTRODUCTION: Tubo-ovarian carcinomas (OCs) are highly sensitive to platinum-based neoadjuvant chemotherapy (NACT) but almost never demonstrate complete pathologic response. METHODS: We analyzed paired primary and residual tumor tissues from 30 patients with hereditary BRCA1/2-driven OCs (BRCA1: 17; BRCA2: 13), who were treated by carboplatin/paclitaxel NACT (median number of cycles: 3, range: 3-6). BRCA1/2 and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.